Takamatsu S, Maruyama M, Sugano N, Katada M, Ebuchi M
Dept. of Surgery, Tokyo Metropolitan Ohkubo Hospital.
Gan To Kagaku Ryoho. 1995 Sep;22(11):1619-21.
We administered methotrexate (MTX) and 5-fluorouracil (5-FU) into the peritoneal cavity as chemotherapy after operation for advanced gastric cancer from a port implanted subcutaneously during the operation, every or every other week. It has been said that MTX tends to be kept in the peritoneal cavity, so the kinetics of MTX is important when it was administered there in. We investigated the concentrations of MTX in the peritoneal cavity and serum with infusion into the peritoneal cavity (IP), and compared it with intraarterial (IA) and intravenous (IV) administration. The results were the lower serum concentration of MTX in IP than in both IA and IV at 1-2 hours after infusion, but thereafter it was the same level in each group. The intraperitoneal concentration of MTX was lower than the detectable level at 24-48 hours after infusion. On the other hand, we investigated the side effects of this therapy, and only one of 20 cases given therapy many times had nausea and vomiting. So the intraperitoneal infusion therapy of MTX and 5-FU seemed to be safe.
我们在晚期胃癌手术后，通过术中植入皮下的端口，每隔一周或每隔两周向腹腔内注入甲氨蝶呤（MTX）和5-氟尿嘧啶（5-FU）进行化疗。据说MTX倾向于滞留在腹腔内，因此在腹腔内给药时MTX的动力学很重要。我们通过腹腔内注入（IP）研究了腹腔和血清中甲氨蝶呤的浓度，并将其与动脉内（IA）和静脉内（IV）给药进行比较。结果是，输注后1-2小时，IP组中甲氨蝶呤的血清浓度低于IA组和IV组，但此后每组中的水平相同。输注后24-48小时，腹腔内甲氨蝶呤的浓度低于可检测水平。另一方面，我们研究了这种治疗方法的副作用，在多次接受治疗的20例患者中，只有1例出现恶心和呕吐。因此，MTX和5-FU的腹腔内输注疗法似乎是安全的。
